Kazazian Asset Management LLC Invests $399,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kazazian Asset Management LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 560 shares of the biopharmaceutical company’s stock, valued at approximately $399,000.

A number of other institutional investors also recently made changes to their positions in the stock. Harvest Fund Management Co. Ltd raised its holdings in shares of Regeneron Pharmaceuticals by 27.4% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 6,360 shares of the biopharmaceutical company’s stock worth $4,388,000 after acquiring an additional 1,366 shares during the last quarter. Vinva Investment Management Ltd grew its position in shares of Regeneron Pharmaceuticals by 45.5% in the fourth quarter. Vinva Investment Management Ltd now owns 3,779 shares of the biopharmaceutical company’s stock valued at $2,655,000 after purchasing an additional 1,182 shares during the period. VSM Wealth Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $107,000. Xponance Inc. grew its position in shares of Regeneron Pharmaceuticals by 3.1% in the fourth quarter. Xponance Inc. now owns 16,272 shares of the biopharmaceutical company’s stock valued at $11,591,000 after purchasing an additional 482 shares during the period. Finally, Generali Asset Management SPA SGR purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $8,091,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Robert W. Baird lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Trading Down 2.0 %

NASDAQ:REGN opened at $664.96 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The business’s 50-day simple moving average is $692.84 and its 200 day simple moving average is $823.99. The stock has a market cap of $72.70 billion, a price-to-earnings ratio of 17.37, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.